prochlorperazine IM
Selected indexed studies
- Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. (Cell, 2020) [PMID:32142680]
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. (Headache, 2026) [PMID:41321235]
- Sustained Endocytosis Inhibition via Locally-Injected Drug-Eluting Hydrogel Improves ADCC-Mediated Antibody Therapy in Colorectal Cancer. (Adv Sci (Weinh), 2025) [PMID:39560161]
_Worker-drafted node — pending editorial review._
Connections
prochlorperazine IM is a side effect of
Sources
- Droperidol for the treatment of acute migraine headaches. (2015) pubmed
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. (2026) pubmed
- Droperidol vs. prochlorperazine for benign headaches in the emergency department. (2001) pubmed
- Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. (2020) pubmed
- Sustained Endocytosis Inhibition via Locally-Injected Drug-Eluting Hydrogel Improves ADCC-Mediated Antibody Therapy in Colorectal Cancer. (2025) pubmed
- Cancer ATF4-mediated CD58 endocytosis impairs anti-tumor immunity and immunotherapy. (2025) pubmed
- G4-binding drugs, chlorpromazine and prochlorperazine, repurposed against COVID-19 infection in hamsters. (2023) pubmed
- A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty. (1996) pubmed
- Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. (1996) pubmed
- Frequency of adverse reactions to prochlorperazine in the ED. (2000) pubmed